Benjamin E. Gewurz

A multi-omics resource of B cell activation reveals genetic mechanisms for immune-mediated diseases

This study profiles B cell activation states using multi-omics data to identify genetic mechanisms underlying immune-mediated diseases.

A Human Genome-wide CRISPR-Cas9 Screen Reveals Host Factors That Support Epstein-Barr Virus B cell infection

This study uses a genome-wide CRISPR-Cas9 screen to identify host factors essential for EBV B cell infection, revealing new pathways and potential therapeutic targets.

The diverse functions of viral microproteins

A >50,000-element viral smORF library screened by growth, MHC-I, ER stress, Perturb-seq and mass spectrometry yields >2,000 active microproteins and shows EBV BNLF2b inhibits PKA by mimicry.

A tonsil organoid model reveals Epstein-Barr virus infected germinal center B cell states during primary infection

This study develops an EBV-infected tonsil organoid model to study B cell states and antiviral responses during primary infection, revealing unique transcriptional programs and immune interactions.

Systematic investigation reveals extensive Epstein-Barr virus transcriptional regulation of the human genome

This study systematically investigates EBV transcriptional regulators' interactions with the human genome, identifying extensive gene expression alterations and chromatin changes.

Epstein-Barr virus transformation creates a methionine-dependent ferroptosis vulnerability in B cells

This study shows that methionine restriction induces ferroptosis in EBV-transformed B cells by promoting transsulfuration and glutathione synthesis, and that targeting methionine metabolism can impair tumor growth.

Arginine Metabolism Supports De Novo Pyrimidine Biosynthesis to Block DNA Damage and Maintain Epstein-Barr Virus Latency

This study identifies arginine metabolism as critical for maintaining Epstein-Barr virus latency by supporting de novo pyrimidine biosynthesis, and shows that restricting arginine or disrupting pyrimidine synthesis can induce EBV reactivation.

The HUSH Complex Dictates EBV-transformed B cell Sensitivity to NK Cell Surveillance Through Repression of NKG2A Ligand γ-Proto-cadherin

The paper identifies the HUSH complex as a regulator of EBV-transformed B cell sensitivity to NK cell surveillance by repressing the NKG2A ligand γ-protocadherin.

EBNA1 INHIBITORS REVEAL CDC7 AND POU2F1 AS DIRECT FUNCTIONAL TARGETS IN EBV EPITHELIAL CANCERS

This study identifies CDC7 and POU2F1 as direct targets of EBNA1 in EBV+ epithelial cancers using VK1727 inhibition, revealing new therapeutic strategies.

CRISPR Screens Reveal Epstein-Barr Virus-activated JunB as a Key Lymphoblastoid B cell Dependency Factor that Represses Cyclin Dependent Kinase Inhibitor P18INK4c

This study identifies JunB as a key dependency factor in EBV-infected B cells that represses p18INK4c, revealing a potential therapeutic target for EBV-associated cancers.

A CRISPR-Cas9 screen Reveals STEEP1 as a Key Host Dependency Factor for Epstein-Barr Virus Latent Membrane Protein 1 Trafficking and Signaling

This paper identifies STEEP1 as a host factor critical for LMP1 trafficking and signaling using a CRISPR-Cas9 screen, showing its role in NF-kB and MAP kinase pathway activation.

Epstein-Barr Virus Latent Membrane Protein 1 Suppresses Ferroptosis via Pentose Phosphate Pathway and Glutathione Metabolism

This study shows that EBV's LMP1 protein prevents ferroptosis by enhancing glutathione and NADPH through the pentose phosphate pathway and cystine uptake.

Enhanced EBNA2-dependent activity in EBV-transformed B cells from patients with multiple sclerosis

This study shows that EBNA2 activity is increased in MS patients, altering gene expression and chromatin accessibility in EBV-transformed B cells.

Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV associated gastric cancer

The paper investigates the effects of decitabine on EBV-associated gastric cancer by integrating transcriptomic and methylome data, revealing retinoic acid pathway activation as a potential therapeutic target.

Epstein-Barr Virus Latent Membrane Protein 1 targets cIAP1, cIAP2 and TRAF2 for Proteasomal Degradation to Activate the Non-canonical NF-κB Pathway

This study identifies how LMP1's TES1 region activates non-canonical NF-κB signaling by degrading cIAP1, cIAP2, and TRAF2, distinct from CD40.

Epstein-Barr Virus Encoded lncRNAs Control the Viral Lytic Switch

This study identifies viral lncRNAs that regulate EBV reactivation by interacting with CTCF and modulating enhancer-promoter looping.

Human cytomegalovirus infection coopts chromatin organization to diminish TEAD1 transcription factor activity

This study shows HCMV infection disrupts chromatin organization and reduces TEAD1 activity through multiple mechanisms, linking it to genetic risk loci for eye and ear development.

Insights into the Absence of Lymphoma Despite Fulminant Epstein-Barr Virus Infection in Patients with XIAP Deficiency

This study investigates why XLP-2 patients, with XIAP deficiency, avoid EBV-driven lymphoma despite severe EBV infection, finding that XIAP loss impairs EBV-induced B-cell outgrowth and promotes apoptosis.

Epstein-Barr Virus Latent Membrane Protein 1 Subverts IMPDH pathways to drive B-cell oncometabolism

This study identifies LMP1-driven metabolic reprogramming in B-cells, showing that IMPDH inhibition sensitizes EBV-transformed cells to apoptosis, suggesting therapeutic targets for LMP1-driven lymphomas.

The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program

This study shows that WAPL suppresses LMP1 and LMP2A expression in EBV latency I by altering DNA looping and histone marks, preventing the transition to latency II.